Skip to content

Transcutaneous Application of Gaseous CO2

The Effect of Transcutaneous Application of Gaseous CO2 on Diabetic Chronic Wound Healing

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04561609
Enrollment
120
Registered
2020-09-23
Start date
2023-05-15
Completion date
2025-09-22
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)

Keywords

transcutaneous CO2 application

Brief summary

The research is designed to evaluate influence of transcutaneous application of CO2 (carbon dioxide) on chronic wound healing. Transcutaneous application of CO2 is known to have immediate effect on vasodilatation and elevates oxygen release from Hb via the Bohr effect. After repetition of the therapies neoangiogenesis is induced. Impairment of microcirculation is one of the causes of impared wound healing and improvement in circulation could have positive effect on wound healing, reduction of the wound area and granulation of the wound bed (Falanga score).

Detailed description

Transcutaneous application of gaseous CO2 showed to be a successful adjuvant therapy in treatment of chronic wounds in diabetic patients (PMID: 32633896). In this intervention technique, therapeutic concentrations of medical-grade CO2 are applied to the skin's surface in a safe, non-invasive manner. The main therapeutic mechanism is derived from the human body's natural response to locally increased CO2 concentration. Because vasodilatory capacity is impaired in diabetic foot, these mechanisms enhance local microvascular perfusion, thereby improving tissue oxygenation in patients with DFUs. Furthermore, although the researchers primarily focus on CO2 therapy as an intervention method, its efficacy is also suggested in preventing DFUs. We plan to enrole 120 patients, 80 into the study arm that will recieve CO2 therapy and 40 for a control group wothout CO2 therapy. All 120 patienrs will receive standard wound care. Aditionally, only study group will receive 20 treatments with CO2 (each workday for 4 weeks). Lower part of the body will be inserted into therapeutic wrap that is filled with 99.9% CO2 gas for 50 minutes. In both groups investigator will evaluate wound status (size, Falanga score of the wound bed) before first and after 4 weeks of treatment. Main outcome measure will be ratio of the completely heald wounds, reduction of the wound size in non healed wounds and status of the wound bed in non healed wounds after 4 weeks of treatment. Possible side effects of the CO2 therapy will be monitored.

Interventions

OTHERTranscutaneous CO2 application

Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 50 minutes. Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only).

Sponsors

University Medical Centre Ljubljana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The use of transcutaneous application of gaseous CO2 for treatment of diabetic chronic wound. A Control group receives standard of care.

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* confirmed diagnosis of DM Type 1 or Type 2, * confirmed diagnosis of a non-healing DFU without clinical signs of infection, * being able to provide informed consent for the participation, and

Exclusion criteria

* patients with severe comorbidities: deep vein thrombosis, chronic kidney diseases grade III and IV, chronic heart diseases NYHA (New York Heart Association) III and IV, patients with known malignant diseases, patients with progressive infection, signs of systemic infection with elevated inflammatory markers or osteomyelitis

Design outcomes

Primary

MeasureTime frameDescription
Ratio of completely healed woundsafter 4 weeks of therapy with CO2 or standard of careThe ratio of the completely healed wounds without exudate on 2 consecutive visits

Secondary

MeasureTime frameDescription
reduction of the wound size of the unhealed woundsafter 4 weeks of therapy with CO2 or standard of carethe ratio of the reduction of the wound size in wound that are not completely helaed after 4 weeks of treatment

Countries

Croatia, Slovenia

Contacts

PRINCIPAL_INVESTIGATORIgor Frangez, PhD, MD, DDS

UCMLjubljana

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026